The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
Open accessAbstract
The valine at position 82 (Val 82) in the active site of the human immunodeficiency virus (HIV) protease mutates in response to therapy with the protease inhibitor ritonavir. By using the X-ray crystal structure of the complex of HIV protease and ritonavir, the potent protease inhibitor ABT-378, which has a diminished interaction with Val 82, was designed. ABT-378 potently inhibited wild-type and mutant HIV protease ( K i = 1.3 to 3.6 pM), blocked the replication of laboratory and clinical strains of HIV type 1 (50% effective concentration [EC 50 ], 0.006 to 0.017 μM), and maintained high potency against mutant HIV selected by ritonavir in vivo (EC 50 , ≤0.06 μM). The metabolism of ABT-378 was strongly inhibited by ritonavir in vitro. Consequently, following concomitant oral administration of ABT-378 and ritonavir, the concentrations of ABT-378 in rat, dog, and monkey plasma exceeded the in vitro antiviral EC 50 in the presence of human serum by >50-fold after 8 h. In healthy human volunteers, coadministration of a single 400-mg dose of ABT-378 with 50 mg of ritonavir enhanced the area under the concentration curve of ABT-378 in plasma by 77-fold over that observed after dosing with ABT-378 alone, and mean concentrations of ABT-378 exceeded the EC 50 for >24 h. These results demonstrate the potential utility of ABT-378 as a therapeutic intervention against AIDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., & De Clercq, E. (1988) · Journal of Virological Methods · doi:10.1016/0166-0934(88)90134-6 · Cited by 1,642
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
Molla, A., Korneyeva, M., Gao, Q., Vasavanonda, S., Schipper, P. J., Mo, H.-M., Markowitz, M., Chernyavskiy, T., Niu, P., Lyons, N., et al. (1996) · Nature Medicine · doi:10.1038/nm0796-760 · Cited by 762
Self-citationNovel Fluorogenic Substrates for Assaying Retroviral Proteases by Resonance Energy Transfer
Matayoshi, E. D., Wang, G. T., Krafft, G. A., & Erickson, J. (1990) · Science · doi:10.1126/science.2106161 · Cited by 592
Danner, S. A., Carr, A., Leonard, J. M., Lehman, L. M., Gudiol, F., Gonzales, J., Raventos, A., Rubio, R., Bouza, E., Pintado, V., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332303 · Cited by 567
Self-citationKempf, D. J., Marsh, K. C., Denissen, J. F., McDonald, E., Vasavanonda, S., Flentge, C. A., Green, B. E., Fino, L., Park, C. H., & Kong, X. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2484 · Cited by 560
Self-citationRandomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
Cameron, D. W., Heath-Chiozzi, M., Danner, S., Cohen, C., Kravcik, S., Maurath, C., Sun, E., Henry, D., Rode, R., Potthoff, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)04161-5 · Cited by 536
Self-citationA Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection
Markowitz, M., Saag, M., Powderly, W. G., Hurley, A. M., Hsu, A., Valdes, J. M., Henry, D., Sattler, F., Marca, A. L., Leonard, J. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332204 · Cited by 493
Self-citationKempf, D. J., Marsh, K. C., Kumar, G., Rodrigues, A. D., Denissen, J. F., McDonald, E., Kukulka, M. J., Hsu, A., Granneman, G. R., Baroldi, P. A., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.654 · Cited by 417
Self-citationKumar, G. N., Rodrigues, A. D., Buko, A. M., & Denissen, J. F. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12840-1 · Cited by 353
Self-citationKrohn, A., Redshaw, S., Ritchie, J. C., Graves, B. J., & Hatada, M. H. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00115a028 · Cited by 233
Kempf, D. J., Sham, H. L., Marsh, K. C., Flentge, C. A., Betebenner, D., Green, B. E., McDonald, E., Vasavanonda, S., Saldivar, A., Wideburg, N. E., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970636+ · Cited by 205
Self-citationMultiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects
Hsu, A., Granneman, G. R., Witt, G., Locke, C., Denissen, J., Molla, A., Valdes, J., Smith, J., Erdman, K., Lyons, N., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.898 · Cited by 184
Self-citationA 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
Stein, D. S., Fish, D. G., Bilello, J. A., Preston, S. L., Martineau, G. L., & Drusano, G. L. (1996) · AIDS · doi:10.1097/00002030-199605000-00006 · Cited by 172
Molla, A., Vasavanonda, S., Kumar, G., Sham, H. L., Johnson, M., Grabowski, B., Denissen, J. F., Kohlbrenner, W., Plattner, J. J., Leonard, J. M., et al. (1998) · Virology · doi:10.1006/viro.1998.9383 · Cited by 171
Self-citationTherapy for Human Immunodeficiency Virus Infection
Wood, A. J. J., Hirsch, M. S., & D'Aquila, R. T. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306103282307 · Cited by 163
Kempf, D. J., Marsh, K. C., Paul, D. A., Knigge, M. F., Norbeck, D. W., Kohlbrenner, W. E., Fino, L. C., Vasavanonda, S., Bryant, P., & Wang, X. C. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.11.2209 · Cited by 143
Self-citationEvaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors.
Greco, W. R., & Hakala, M. T. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)86435-9 · Cited by 109
Recent developments in HIV protease inhibitor therapy
Molla, A., Granneman, G. R., Sun, E., & Kempf, D. J. (1998) · Antiviral Research · doi:10.1016/s0166-3542(98)00011-4 · Cited by 99
Self-citationKumar, G. N., Jayanti, V. K., Lee, R. D., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14888-x · Cited by 64
Self-citationTong, L., Pav, S., Mui, S., Lamarre, D., Yoakim, C., Beaulieu, P. L., & Anderson, P. C. (1995) · Structure · doi:10.1016/s0969-2126(01)00133-2 · Cited by 54
Cited by
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Choy, K.-T., Wong, A. Y.-L., Kaewpreedee, P., Sia, S. F., Chen, D., Hui, K. P. Y., Chu, D. K. W., Chan, M. C. W., Cheung, P. P.-H., Huang, X., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104786 · Cited by 922
Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., Johnson, M., Johnson, D., Lalonde, R., Japour, A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012354 · Cited by 647
Self-citationComputational methods in drug discovery
Leelananda, S. P., & Lindert, S. (2016) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.12.267 · Cited by 639
Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., & Kruger, H. G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113705 · Cited by 625
Metadata
- Authors
- Sham, H. L., Kempf, D. J., Molla, A., Marsh, K. C., Kumar, G. N., Chen, C.-M., Kati, W., Stewart, K., Lal, R., Hsu, A., Betebenner, D., Korneyeva, M., Vasavanonda, S., McDonald, E., Saldivar, A., Wideburg, N., Chen, X., Niu, P., Park, C., Jayanti, V., Grabowski, B., Granneman, G. R., Sun, E., Japour, A. J., Leonard, J. M., Plattner, J. J., & Norbeck, D. W.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1998-12
- Volume
- 42
- Issue
- 12
- Pages
- 3218-3224
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2112857740
- Cited by
- 471
- References
- 21
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.